BridgeBio Pharma
BBIO
244 hedge funds and large institutions have $5.42B invested in BridgeBio Pharma in 2024 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 99 increasing their positions, 81 reducing their positions, and 44 closing their positions.
179% more call options, than puts
Call options by funds: $266M | Put options by funds: $95.3M
22% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 81
5% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 44
1% less funds holding
Funds holding: 247 → 244 (-3)
3.1% less ownership
Funds ownership: 96.21% → 93.11% (-3.1%)
7% less funds holding in top 10
Funds holding in top 10: 15 → 14 (-1)
20% less capital invested
Capital invested by funds: $6.76B → $5.42B (-$1.34B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$73.8M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$37.8M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$23.5M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$20M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$72.7M |
| 2 |
Goldman Sachs
New York
|
-$55.8M |
| 3 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$17.8M |
| 4 |
D.E. Shaw & Co
New York
|
-$17.2M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.5M |
BBIO Hedge Fund Activity: Q1 2024 in Review
244 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2024, worth a combined $5.42B — down 20% from $6.76B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of BBIO and 42 opened new positions — a net loss of 2 holders — while 81 trimmed existing stakes and 99 added.
The largest buyer was Janus Henderson Group, adding an estimated $73.8M. The largest seller was Morgan Stanley, cutting an estimated $72.7M.
- 244 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2024, down from 247 in Q4 2023.
- Funds reported $5.42B of BridgeBio Pharma stock for Q1 2024, down 20% quarter-over-quarter.
- 42 funds opened new BridgeBio Pharma positions in Q1 2024 and 44 closed out, a net change of -2 holders.
- The largest BridgeBio Pharma buyer in Q1 2024 was Janus Henderson Group, an estimated $73.8M added.
- The largest BridgeBio Pharma seller in Q1 2024 was Morgan Stanley, an estimated $72.7M sold.
Based on aggregated 13F filings for Q1 2024.